Experimental Brain Research

, Volume 181, Issue 3, pp 435–446

Mitochondrial respiratory inhibition and oxidative stress elevate β-secretase (BACE1) proteins and activity in vivo in the rat retina

  • Kun Xiong
  • Huaibin Cai
  • Xue-Gang Luo
  • Robert G. Struble
  • Richard W. Clough
  • Xiao-Xin Yan
Research Article

Abstract

Cerebral hypometabolism, oxidative stress and β-amyloid peptide (Aβ) accumulation are key pathological events in Alzheimer’s disease (AD). Beta-secretase (BACE, i.e., BACE1), a prerequisite for Aβ genesis, is elevated in sporadic AD. Recent studies show BACE upregulation in experimental conditions likely associated with energy insufficiency and/or oxidative stress. We investigated the effect of sublethal doses of mitochondrial respiratory inhibitors and potential endogenous oxidative substances on BACE expression in vivo using the retina as a model. Retinas were analyzed biochemically and anatomically 48 h following intraocular applications of mitochondrial complex I, II and IV inhibitors including rotenone, 3-nitropropionic acid and sodium azide, and plaque-containing oxidants including Fe3+ and Aβ42 fibrils (Aβ42f). All agents caused elevations of BACE proteins and β-site amyloid precursor protein (APP) cleavage product, β-CTF, in retinal lysates in a dose-dependant manner. BACE activity and Aβ40 levels were also increased in agent-treated retinas relative to vehicle controls. BACE immunoreactivity in normal adult rat retina was present mostly in the plexiform layers, indicating a localization of the enzyme to synaptic terminals. No apparent change in laminar or cellular distribution of BACE labeling was detected in the experimental retinas. However, signs of neuronal stress including glial activation were observed in agent-treated retinas especially in high dosage groups. Our data suggest that mitochondrial respiratory inhibition and oxidative stress facilitate BACE expression in vivo. In addition, plaque constituents such as Fe3+ and Aβ42f may participate in a self-enforcing cycle of amyloidogenesis via BACE upregulation.

Keywords

β-Amyloid Hypometabolism Aging Dementia Alzheimer’s disease 

References

  1. Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10(Suppl): S18–S25PubMedCrossRefGoogle Scholar
  2. Bennett MC, Mlady GW, Kwon YH, Rose GM (1996) Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase. J Neurochem 66:2606–2611PubMedCrossRefGoogle Scholar
  3. Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R (2004) Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer’s disease beta-secretase (BACE-1). J Neural Transm 111:523–536PubMedCrossRefGoogle Scholar
  4. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 165:3–12PubMedGoogle Scholar
  5. Butterfield DA, Boyd-Kimball D (2004) Amyloid beta-peptide (1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14:426–432PubMedCrossRefGoogle Scholar
  6. Desire L, Bourdin J, Loiseau N, Peillon H, Picard V, De Oliveira C, Bachelot F, Leblond B, Taverne T, Beausoleil E, Lacombe S, Drouin D, Schweighoffer F (2005) RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem 280:37516–37525PubMedCrossRefGoogle Scholar
  7. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, Wagenpfeil S, Minoshima S, Schwaiger M, Kurz A (2005) Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 64:102–107PubMedGoogle Scholar
  8. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59:1381–1389PubMedCrossRefGoogle Scholar
  9. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, Saito Y, Murayama S (2006) Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer’s disease brains. Neurosci Res 54:24–29PubMedCrossRefGoogle Scholar
  10. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA (2004) Oxidative stress and redox-active iron in Alzheimer’s disease. Ann N Y Acad Sci 1012:179–182PubMedCrossRefGoogle Scholar
  11. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 51:783–786PubMedCrossRefGoogle Scholar
  12. Huang LS, Sun G, Cobessi D, Wang AC, Shen JT, Tung EY, Anderson VE, Berry EA (2006) 3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem 281:5965–5972PubMedCrossRefGoogle Scholar
  13. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW (2000) Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer’s disease beta-secretase. J Biol Chem 275:33729–33737PubMedCrossRefGoogle Scholar
  14. Jen LS, Hart AJ, Jen A, Relvas JB, Gentleman SM, Garey LJ, Patel AJ (1998) Alzheimer’s peptide kills cells of retina in vivo. Nature 392:140–141PubMedCrossRefGoogle Scholar
  15. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693–11709PubMedCrossRefGoogle Scholar
  16. LeVine H III (1993): Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2:404–410PubMedCrossRefGoogle Scholar
  17. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA 101:3632–3637PubMedCrossRefGoogle Scholar
  18. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278–294PubMedCrossRefGoogle Scholar
  19. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD Eur J Nucl Med Mol Imaging 32:486–510PubMedCrossRefGoogle Scholar
  20. Nunan J, Small DH (2002) Proteolytic processing of the amyloid-beta protein precursor of Alzheimer’s disease. Essays Biochem 38:37–49PubMedGoogle Scholar
  21. Ojaimi J, Masters CL, Opeskin K, McKelvie P, Byrne E (1999) Mitochondrial respiratory chain activity in the human brain as a function of age. Mech Ageing Dev 111:39–47PubMedCrossRefGoogle Scholar
  22. Ong WY, Farooqui AA (2005) Iron, neuroinflammation, and Alzheimer’s disease. J Alzheimers Dis 8:183–200; discussion 209–215Google Scholar
  23. Parihar MS, Brewer GJ (2007) Mitoenergetic failure in Alzheimer’s disease. Am J Physiol Cell Physiol 292:C8–C23PubMedCrossRefGoogle Scholar
  24. Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem 96:1–13PubMedCrossRefGoogle Scholar
  25. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2005) Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 102:8299–8302PubMedCrossRefGoogle Scholar
  26. Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924:17–25PubMedCrossRefGoogle Scholar
  27. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMedGoogle Scholar
  28. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003) Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 23:10756–10764PubMedGoogle Scholar
  29. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 103:18727–18732PubMedCrossRefGoogle Scholar
  30. Swerdlow RH, Khan SM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses 63:8–20PubMedCrossRefGoogle Scholar
  31. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10:279–288PubMedCrossRefGoogle Scholar
  32. Tamagno E, Bardini P, Guglielmotto M, Danni O, Tabaton M (2006) The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med 41:202–212PubMedCrossRefGoogle Scholar
  33. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, Song W (2005) Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112:455–469PubMedCrossRefGoogle Scholar
  34. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ (2002) Alpha- and beta-secretase: profound changes in Alzheimer’s disease. Biochem Biophys Res Commun 299:373–376PubMedCrossRefGoogle Scholar
  35. Valla J, Berndt JD, Gonzalez-Lima F (2001) Energy hypometabolism in posterior cingulate cortex of Alzheimer’s patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21:4923–4930PubMedGoogle Scholar
  36. Velliquette RA, O’Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis. J Neurosci 25:10874–10883PubMedCrossRefGoogle Scholar
  37. Walsh DT, Bresciani L, Saunders D, Manca MF, Jen A, Gentleman SM, Jen LS (2005) Amyloid beta peptide causes chronic glial cell activation and neurodegeneration after intravitreal injection. Neuropathol Appl Neurobiol 31:491–502PubMedCrossRefGoogle Scholar
  38. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW (2004) Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009:1–8PubMedCrossRefGoogle Scholar
  39. Wong-Riley M, Antuono P, Ho KC, Egan R, Hevner R, Liebl W, Huang Z, Rachel R, Jones J (1997) Cytochrome oxidase in Alzheimer’s disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 37:3593–3608PubMedCrossRefGoogle Scholar
  40. Yan XX, Li T, Rominger CM, Prakash SR, Wong PC, Olson RE, Zaczek R, Li YW (2004) Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. J Neurosci 24:2942–2952PubMedCrossRefGoogle Scholar
  41. Yan XX, Xiong K, Luo XG, Struble RG, Clough RW (2007) β-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. J Comp Neurol 501:52–69PubMedCrossRefGoogle Scholar
  42. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9:3–4PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Kun Xiong
    • 1
    • 3
  • Huaibin Cai
    • 2
  • Xue-Gang Luo
    • 3
  • Robert G. Struble
    • 4
  • Richard W. Clough
    • 1
  • Xiao-Xin Yan
    • 1
  1. 1.Department of AnatomySouthern Illinois University School of MedicineCarbondaleUSA
  2. 2.Laboratory of Neurogenetics, National Institute on AgingNational Institutes of HealthBethesdaUSA
  3. 3.Department of Anatomy and NeurobiologyCentral South University Xiangya Medical SchoolChangshaChina
  4. 4.Department of Neurology and Center for Alzheimer DiseaseSouthern Illinois University School of MedicineSpringfieldUSA

Personalised recommendations